Sage Mountain Advisors LLC Purchases 623 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

16 Jul 2025, 11:18 by Scott Moore · The Cerbat Gem

Sage Mountain Advisors LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 10.2% during the first quarter, Holdings Channel reports. The institutional investor owned 6,735 shares of the biopharmaceutical company’s stock after acquiring an additional 623 shares during the quarter. Sage Mountain Advisors LLC’s holdings in Gilead Sciences were worth $755,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. FMR LLC raised its position in shares of Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Gilead Sciences by 3.1% in the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company’s stock valued at $3,293,822,000 after purchasing an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Gilead Sciences by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company’s stock valued at $2,608,337,000 after purchasing an additional 749,047 shares during the last quarter. Norges Bank purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $1,789,254,000. Finally, Northern Trust Corp raised its position in shares of Gilead Sciences by 19.7% in the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock valued at $1,377,707,000 after purchasing an additional 2,458,954 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Down 2.7%

Shares of GILD stock opened at $109.06 on Wednesday. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a 1 year low of $70.33 and a 1 year high of $119.96. The stock has a fifty day moving average of $108.15 and a two-hundred day moving average of $104.91. The firm has a market capitalization of $135.66 billion, a PE ratio of 22.96, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the previous year, the business earned ($1.32) EPS. The company’s quarterly revenue was down .3% compared to the same quarter last year. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.90%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences’s payout ratio is 66.53%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Monday, June 30th. The stock was sold at an average price of $110.45, for a total value of $1,104,500.00. Following the transaction, the chief executive officer directly owned 615,725 shares of the company’s stock, valued at $68,006,826.25. This represents a 1.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the sale, the insider owned 121,152 shares of the company’s stock, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 61,000 shares of company stock valued at $6,623,445. 0.27% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GILD. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, March 27th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price objective on the stock. Oppenheimer dropped their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, April 25th. Finally, Morgan Stanley lifted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $111.38.

Get Our Latest Stock Report on Gilead Sciences

Gilead Sciences Profile

(Free Report)